Resultados da busca - Jan Walewski

Refinar Resultados
  1. 1
    Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up por Hervé Tilly, Umberto Vitolo, Jan Walewski, María Gomes da Silva, Ofer Shpilberg, Marc André, Michael Pfreundschuh, M. Dreyling

    Publicado em 2012
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  2. 2
    Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia

    Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia por Dieter Hoelzer, Nicola Gökbuget, W. Digel, Thomas Faak, Michael Kneba, Regina Reutzel, Joanna Romejko‐Jarosińska, Jacek Zwoliński, Jan Walewski

    Publicado em 2002
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  3. 3
    Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up por M. Dreyling, Elı́as Campo, Olivier Hermine, Mats Jerkeman, Steven Le Gouill, Simon Rule, Ofer Shpilberg, Jan Walewski, Marco Ladetto

    Publicado em 2017
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  4. 4
    Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up por M. Dreyling, Carsten Geisler, Olivier Hermine, Hanneke C. Kluin‐Nelemans, Steven Le Gouill, Simon Rule, Ofer Shpilberg, Jan Walewski, Marco Ladetto

    Publicado em 2014
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  5. 5
    A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial)

    A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY1... por Graham M. Mead, Sharon Barrans, Wendi Qian, Jan Walewski, John Radford, Max Wolf, Simon Clawson, Sally Stenning, Claire L. Yule, Andrew Jack

    Publicado em 2008
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  6. 6
    Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study

    Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study por Michael A. Rieger, Anders Österborg, Ruth Pettengell, Darrell White, Devinder Gill, Jan Walewski, Evelyn Kuhnt, Markus Loeffler, Michael Pfreundschuh, Anthony D. Ho

    Publicado em 2010
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  7. 7
    Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up por Hervé Tilly, María Gomes da Silva, Umberto Vitolo, Andrew Jack, Michel Meignan, Armando López‐Guillermo, Jan Walewski, M. André, Peter Johnson, Michael Pfreundschuh, Marco Ladetto

    Publicado em 2015
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  8. 8
    Comparison of ABVD and Alternating or Hybrid Multidrug Regimens for the Treatment of Advanced Hodgkin's Lymphoma: Results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519)

    Comparison of ABVD and Alternating or Hybrid Multidrug Regimens for the Treatment of Advanced Hodgkin's Lymphoma: Results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN971... por Peter Johnson, John Radford, Michael Cullen, Matthew R. Sydes, Jan Walewski, Andrew Jack, Kenneth MacLennan, Sally Stenning, Simon Clawson, Paul Smith, David Ryder, Barry W. Hancock

    Publicado em 2005
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  9. 9
    Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial

    Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase... por Pier Luigi Zinzani, Nuriet K. Khuageva, Huaqing Wang, Bernardo Garicochea, Jan Walewski, Achiel Van Hoof, Pierre Soubeyran, Dolores Caballero, Rena Buckstein, Dixie‐Lee Esseltine, Panteli Theocharous, Christopher Enny, Eugene Zhu, Yusri Elsayed, Bertrand Coiffier

    Publicado em 2012
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  10. 10
    Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse

    Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse por Craig H. Moskowitz, Jan Walewski, Auayporn Nademanee, Tamás Masszi, Edward Agura, Jerzy Hołowiecki, Muneer H. Abidi, Andy I. Chen, Patrick J. Stiff, Simonetta Viviani, Veronika Bachanová, Anna Sureda, Teresa McClendon, Connie Lee, Julie Lisano, John Sweetenham

    Publicado em 2018
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  11. 11
    First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial

    First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial por Anton Hagenbeek, Ole Gadeberg, Peter Johnson, Lars Møller Pedersen, Jan Walewski, Andrzej Hellmann, Brian K. Link, Tadeusz Robak, Marek Z. Wojtukiewicz, Michael Pfreundschuh, Michael Kneba, Andreas Engert, Pieter Sonneveld, Mimi Folden Flensburg, Jørgen Holm Petersen, Nedjad Losic, John Radford

    Publicado em 2008
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  12. 12
    Efficacy and safety of pembrolizumab in relapsed/refractory primary mediastinal large B‐cell lymphoma (rrPMBCL): interim analysis of the KEYNOTE‐170 phase 2 trial

    Efficacy and safety of pembrolizumab in relapsed/refractory primary mediastinal large B‐cell lymphoma (rrPMBCL): interim analysis of the KEYNOTE‐170 phase 2 trial por Pier Luigi Zinzani, Catherine Thiéblemont, В Я Мельниченко, Dzhelil Osmanov, Krimo Bouabdallah, Jan Walewski, Alejandro Majlis, Laura Fogliatto, M. D. Caballero Barrigón, Christian Bach, Zafer Gülbaş, Muhi̇t Özcan, Gilles Salles, Margaret A. Shipp, Arun Balakumaran, Sabine Chlosta, Arkendu Chatterjee, Philippe Armand

    Publicado em 2017
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  13. 13
    Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma: Final Analysis of KEYNOTE-170

    Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma: Final Analysis of KEYNOTE-170 por Pier Luigi Zinzani, Catherine Thiéblemont, В Я Мельниченко, Krimo Bouabdallah, Jan Walewski, Alejandro Majlis, Laura Fogliatto, Alejandro Martı́n, Beth Christian, Zafer Gülbaş, Muhi̇t Özcan, Guilherme Fleury Perini, Hervé Ghesquières, Margaret A. Shipp, Seth Thompson, Samhita Chakraborty, Patricia Marinello, Philippe Armand

    Publicado em 2023
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  14. 14
    Early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma: long-term results of a randomised, phase 3 trial

    Early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma: long-term results of a randomised, phase 3 trial por Michael Northend, William Wilson, Kushani Ediriwickrema, Laura Clifton‐Hadley, Wendi Qian, Zaynab Rana, Tanya-Louise Martin, William Townsend, Moya Young, Fiona Miall, David Cunningham, Jan Walewski, Burhan Ferhanoğlu, Kim Linton, Amanda Johnston, John F. Seymour, David C. Linch, Kirit M. Ardeshna

    Publicado em 2025
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  15. 15
    Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL

    Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL por Christian H. Geisler, Mars B. van ’t Veer, Jesper Jurlander, Jan Walewski, Geir E. Tjønnfjord, Maija Itälä Remes, Eva Kimby, Tomáš Kozák, Aaron Polliack, Ka Lung Wu, Shulamiet Wittebol, Martine C. J. Abrahamse-Testroote, Jeanette K. Doorduijn, Wendimagegn Alemayehu, Marinus H. J. van Oers

    Publicado em 2014
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  16. 16
    Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network

    Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network por Chan Y. Cheah, Anupkumar George, Eva Giné, Annalisa Chiappella, Hanneke C. Kluin‐Nelemans, Wojciech Jurczak, Katarzyna Krawczyk, Heidi Móciková, Pavel Klener, D. Šálek, Jan Walewski, Michał Szymczyk, Lukáš Smolej, Rebecca Auer, David Ritchie, Luca Arcaini, Michael E. Williams, Martin Dreyling, John F. Seymour

    Publicado em 2013
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  17. 17
    Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial

    Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial por Bertrand Coiffier, Evgenii A. Osmanov, Xiaonan Hong, Adriana Scheliga, Jiřı́ Mayer, Fritz Offner, Simon Rule, Adriana Teixeira, Jan Walewski, Sven de Vos, Michael Crump, Ofer Shpilberg, Dixie‐Lee Esseltine, Eugene Zhu, Christopher Enny, Panteli Theocharous, Helgi van de Velde, Yusri Elsayed, Pier Luigi Zinzani

    Publicado em 2011
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  18. 18
    A comprehensive flow-cytometry-based immunophenotypic characterization of Burkitt-like lymphoma with 11q aberration

    A comprehensive flow-cytometry-based immunophenotypic characterization of Burkitt-like lymphoma with 11q aberration por Grzegorz Rymkiewicz, Beata Grygalewicz, Magdalena Chechlińska, Katarzyna Błachnio, Zbigniew Bystydzieński, Joanna Romejko‐Jarosińska, Renata Woroniecka, Michalina Zajdel, Katarzyna Domańska‐Czyż, David Martin‐García, Ferran Nadeu, Paweł Swoboda, Jolanta Rygier, Barbara Pieńkowska‐Grela, Jan Konrad Siwicki, Monika Prochorec–Sobieszek, Itziar Salaverría, Reiner Siebert, Jan Walewski

    Publicado em 2018
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  19. 19
    Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy

    Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy por David J. Straus, Graham P. Collins, Jan Walewski, Pier Luigi Zinzani, Andrew Grigg, Anna Sureda, Árpád Illés, Tae Min Kim, Sergey Alekseev, Lena Specht, Valéria Buccheri, Anas Younes, Joseph M. Connors, Andres Forero‐Torres, Keenan Fenton, Ashish Gautam, Indra Purevjal, Rachael Liu, Andrea Gallamini

    Publicado em 2020
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  20. 20
    Confirmation of the Mantle-Cell Lymphoma International Prognostic Index in Randomized Trials of the European Mantle-Cell Lymphoma Network

    Confirmation of the Mantle-Cell Lymphoma International Prognostic Index in Randomized Trials of the European Mantle-Cell Lymphoma Network por Eva Hoster, Wolfram Klapper, Olivier Hermine, Hanneke C. Kluin‐Nelemans, Jan Walewski, Achiel Van Hoof, Marek Trněný, Christian H. Geisler, Francesco Di Raimondo, Michał Szymczyk, Stephan Stilgenbauer, Catherine Thiéblemont, Michael Hallek, Roswitha Forstpointner, Christiane Pott, Vincent Ribrag, Jeanette K. Doorduijn, Wolfgang Hiddemann, Martin Dreyling, Michael Unterhalt

    Publicado em 2014
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:

Ferramentas de busca: